OncoSec Medical Inc (ONCSQ)

[hschlauch]

I think the most important and insightful data will be shared in a couple days.

For example, what exactly were the pre-treatment TIL percentages in patients who responded or did not respond? Were non-responders' TIL populations very low initially? Are they actually elevating the PD-1 and CTLA-4 TIL phenotypes following EP IL-12 DNA plasmid treatments? At what point in the treatment cycles did some folks respond and what are response durations looking like?

What I think is most interesting about this small dataset is that there were more complete responders than partial responders. This suggests to me that for those patients who respond in the trial population, they are generally responding VERY WELL, so much so that all signs of cancer are gone. If the trial participants were true monotherapy Keytruda non-responders, and the trial size were larger, I think it would be very difficult for competing or synergistic companies to ignore the data. Again, beware this was a small dataset, but interestingly the complete response rates were greater than the partial response rates, thus supporting the retrospective analysis reported earlier this year. That retrospective study also demonstrated more complete responders than partial responders. So why are most patients who respond seeing complete remissions?